CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS
3.4. PRODUCT PIPELINE ANALYSIS
3.5. MARKET DYNAMICS
CHAPTER 4 HIV DRUGS MARKET, BY MEDICATION CLASS
4.1. OVERVIEW
4.2. MULTI-CLASS COMBINATION DRUGS
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Atripla: market size and forecast
4.2.5. Complera: market size and forecast
4.2.6. Prezista: market size and forecast
4.2.7. Stribild: market size and forecast
4.2.8. Triumeq: market size and forecast
4.3. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Combivir: market size and forecast
4.3.5. Emtriva: market size and forecast
4.3.6. Epivir: market size and forecast
4.3.7. Epzicom: market size and forecast
4.3.8. Trizivir: market size and forecast
4.3.9. Truvada: market size and forecast
4.3.10. Viread: market size and forecast
4.4. NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Edurant: market size and forecast
4.4.5. Rescriptor: market size and forecast
4.4.6. Sustiva: market size and forecast
4.4.7. Viramune: market size and forecast
4.5. PROTEASE INHIBITORS (PIS)
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
4.5.4. Aptivus: market size and forecast
4.5.5. Crixivan: market size and forecast
4.5.6. Kaletra: market size and forecast
4.5.7. Lexiva: market size and forecast
4.5.8. Norvir: market size and forecast
4.5.9. Reyataz: market size and forecast
4.5.10. Viracept: market size and forecast
4.6. FUSION INHIBITORS
4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast
4.6.4. Fuzeon: market size and forecast
4.7. ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST
4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.7.4. Selzentry: market size and forecast
4.8. HIV INTEGRASE STRAND TRANSFER INHIBITORS
4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast
4.8.4. Isentress: market size and forecast
4.8.5. Tivicay: market size and forecast
CHAPTER 5 HIV DRUGS MARKET, BY GEOGRAPHY
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.3. EUROPE
5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.4. ASIA-PACIFIC
5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.5. LAMEA
5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
6.1.1. Overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves & developments
6.2. MERCK & CO., INC.
6.2.1. Overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves & developments
6.3. BRISTOL-MYERS SQUIBB
6.3.1. Overview
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves & developments
6.4. GILEAD SCIENCES, INC.
6.4.1. Overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves & developments
6.5. VIIV HEALTHCARE
6.5.1. Overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves & developments
6.6. JOHNSON & JOHNSON
6.6.1. Overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key Strategic Moves & Developments
6.7. F. HOFFMANN-LA ROCHE LTD
6.7.1. Overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key Strategic Moves & Developments
6.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
6.8.1. Overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key Strategic Moves & Developments
6.9. ABBVIE
6.9.1. Overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves & developments
6.10. CIPLA
6.10.1. Overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key Strategic Moves & Developments
LIST OF OTHER PLAYERS IN THE VALUE CHAIN
(These players are not profiled in the report. The same will be included on request)
Daiichi Sankyo
Emcure
Hetero Drugs
Mylan
AstraZeneca